Lv62
1660 积分 2022-06-18 加入
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
7天前
已完结
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
7天前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
13天前
已完结
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs
3个月前
已完结
Targeting the tumour cell surface in advanced prostate cancer
6个月前
已完结
Contactin-4 suppresses antitumor T cell responses by engaging amyloid precursor protein
6个月前
已完结
Fibroblast Activation Protein Alpha (FAPα) as a Promising Target in the Diagnostics and Treatment of Cancer and Fibrotic Diseases: Recent Approaches to Imaging and Assessment of Functional Activity
7个月前
已完结
PSMA-targeted Small Molecule-Drug Conjugates based on a Post-Prolyl Peptidase Cleavable Linker for the Treatment of Prostate Cancer
7个月前
已完结
Exploring the next generation of antibody–drug conjugates
8个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
10个月前
已完结
皖公网安备34019202002308
